Opinion|Videos|January 31, 2025
Where Are We Going? Future Perspectives on Navigating the Treatment Paradigm in Transplant-Eligible NDMM
Panelists discuss how the evolving treatment landscape for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) is being shaped by emerging data on optimal treatment sequencing strategies, both in frontline settings and subsequent lines of therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- As treatments continue to evolve, how do you see the future treatment landscape changing for patients with transplant-eligible NDMM?
- How do the data inform your consideration of treatment sequencing beyond the front line?
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5